title: Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience.
abstract: OBJECTIVE
  To compare the long-term effects of the interleukin-2 receptor antagonist basiliximab versus rabbit antithymocyte globulin as an induction therapy for living-related renal transplantation.
  
  
  METHODS
  This is a prospective, open-label, nonrandomized, controlled study including 213 cases of renal transplant. Immunosuppressive therapy containing calcineurin inhibitors, mycophenolate mofetil and steroids was applied in all cases. The interleukin-2 receptor antagonist group (IL2Ra group) included 108 cases with 20 mg basiliximab induction on Day 0 and Day 4. The other 105 cases comprised the rabbit antithymocyte globulin group (rATG group) with 1.0 mg/kg/day ATG induction from Day 0 to Day 4. The primary endpoint was biopsy-proven acute rejection. Other endpoints included delayed graft function (DGF), graft loss and death.
  
  
  RESULTS
  All patients were followed up for 3 years. Acute rejection rates in the IL2Ra group and the ATG group were 5.6 and 3.8 % (P = 0.781), and the differences in the DGF rates, graft loss and death were insignificant between groups. All-cause infection rates in the IL2Ra and rATG groups were 26.9 and 43.8 % (P = 0.010). Urinary tract infections were more common in the rATG group than in the IL2Ra group (15.2 vs 6.5 %, P = 0.040). Specific viral infection rates were significantly different (18.1 % in rATG group vs 8.3 % in IL2Ra group, P = 0.035).
  
  
  CONCLUSIONS
  IL2Ra and rATG had no significant differences as induction therapies during the perioperative period of living-related renal transplantation, according to acute rejection rates, DGF rates, graft loss, 1- and 3-year patient/graft survival rates. However, the incidence of infection, especially of urinary tract infection and specific viral infection, was higher in rATG-induced patients.
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, 310003, China.|Key Laboratory of Nephropathy, Hangzhou, 310003, Zhejiang Province, China.|Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration of Traditional Chinese Medicine of China, Hangzhou, 310003, China.|Key Laboratory of Multiple Organ Transplantation, Ministry of Health of China, Hangzhou, 310003, China.
authors.forename: Hong-Feng
authors.initials: HF
authors.lastname: Huang
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, 310003, China.|Key Laboratory of Nephropathy, Hangzhou, 310003, Zhejiang Province, China.|Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration of Traditional Chinese Medicine of China, Hangzhou, 310003, China.|Key Laboratory of Multiple Organ Transplantation, Ministry of Health of China, Hangzhou, 310003, China.
authors.forename: Jing-Yi
authors.initials: JY
authors.lastname: Zhou
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, 310003, China.|Key Laboratory of Nephropathy, Hangzhou, 310003, Zhejiang Province, China.|Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration of Traditional Chinese Medicine of China, Hangzhou, 310003, China.|Key Laboratory of Multiple Organ Transplantation, Ministry of Health of China, Hangzhou, 310003, China.
authors.forename: Wen-Qing
authors.initials: WQ
authors.lastname: Xie
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, 310003, China.|Key Laboratory of Nephropathy, Hangzhou, 310003, Zhejiang Province, China.|Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration of Traditional Chinese Medicine of China, Hangzhou, 310003, China.|Key Laboratory of Multiple Organ Transplantation, Ministry of Health of China, Hangzhou, 310003, China.
authors.forename: Jian-Yong
authors.initials: JY
authors.lastname: Wu
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, 310003, China.|Key Laboratory of Nephropathy, Hangzhou, 310003, Zhejiang Province, China.|Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration of Traditional Chinese Medicine of China, Hangzhou, 310003, China.|Key Laboratory of Multiple Organ Transplantation, Ministry of Health of China, Hangzhou, 310003, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Deng
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, 310003, China. chenjianghua@zju.edu.cn.|Key Laboratory of Nephropathy, Hangzhou, 310003, Zhejiang Province, China. chenjianghua@zju.edu.cn.|Kidney Disease Immunology Laboratory, The Third Grade Laboratory, State Administration of Traditional Chinese Medicine of China, Hangzhou, 310003, China. chenjianghua@zju.edu.cn.|Key Laboratory of Multiple Organ Transplantation, Ministry of Health of China, Hangzhou, 310003, China. chenjianghua@zju.edu.cn.
authors.forename: Jiang-Hua
authors.initials: JH
authors.lastname: Chen
mesh_terms: D000046:Academic Medical Centers; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D000077552:Basiliximab; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016030:Kidney Transplantation / Q000379:methods* / Q000401:mortality; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D015996:Survival Rate; D014181:Transplantation Immunology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab
keywords: Antithymocyte globulin; Basiliximab; Induction therapy; Renal transplantation